Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Waters Corporation    WAT

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 05/25 10:02:01 pm
190.65 USD   -1.80%
05/18INSIDER TRADING : WAT) – VP Sold 3,521 shares of Stock
05/11WATERS CORPORAT : WAT) Files An 8-K Submission of Matters to a Vote ..
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Waters Corporation : Waters Selects Ireland’s NIBRT and Prof. Pauline Rudd for Center of Innovation Program Honors

share with twitter share with LinkedIn share with facebook
share via e-mail
04/06/2012 | 12:40pm CEST

Milford, Mass. - 2012-04-05

(click for larger version)
At a ceremony on March 27, Waters honored Prof. Pauline Rudd for her pioneering research in glycobiology. Pictured are (from left to right) Mike Harrington, Ph.D., Vice President, European and Asia Pacific Operations, Waters Division, Prof. Pauline Rudd, and Minister Sean Sherlock TD, Irish Minister for Research and Innovation, Department of Jobs, Enterprise & Innovation.

At a ceremony officiated by Minister Sean Sherlock TD, Irish Minister for Research and Innovation, Department of Jobs, Enterprise & Innovation, Waters Corporation (NYSE:WAT) welcomed the Irish National Institute for Bioprocessing Research and Training (NIBRT) into its Centers of Innovation Program. Waters acknowledged NIBRT and the research team under the direction of Prof. Pauline Rudd, Principal Investigator, for her pioneering contribution to the field of glycobiology, a science of growing importance to both biotherapeutics manufacturers and disease research.

"I am honored to be a part of the Centers of Innovation Program and for what it means to us as we conduct leading-edge research. I regard Waters as more than just an instrument vendor; they are a research partner," said Prof. Rudd.

Prof. Rudd and her team are working with Waters® mass spectrometry based systems to take challenging glycan characterization to the next level. By improving understanding of glycan chemical and molecular structure, scientists can better understand safety and efficacy profiles for a potential molecule, leading directly to novel biotherapeutic options.

 "It's truly exciting to announce and confirm our collaboration with Pauline and NIBRT," said Mike Harrington, PhD, Vice President European and Asia Pacific Operations, Waters Division. "At Waters we believe in the science of what's possible, that there are no problems that science cannot solve. We're lucky to be working with a dedicated partner like NIBRT which believes in the power of science and the importance of research and training.

Biopharmaceuticals are increasingly important to patients and drug manufacturers. By 2014, it is expected that 50% of the top 100 prescribed medications will be biopharmaceuticals, including four of the top five selling drugs. Ireland's exports of pharmaceuticals valued at approximately $55 billion Euros now accounts for more than 50% of the country's GDP.

"In the future most new pharmaceuticals coming on line will be glycoproteins, very large and complex molecules and very challenging to analyze to ensure their safety and efficacy. We're now moving to a new phase of technical development not only for glycan analysis but for full product characterization. So these wonderful instruments from Waters will help us move the field forward and train the next generation of scientists in glycobiology," Prof. Rudd said.

In other news, Waters and NIBRT have established the Complete Product and Processing Characterization Facility (CPPCF) for hands-on laboratory based scientific training and retraining of 'fit-for-purpose' biopharmaceutical analysis, including protein and peptide characterization. The CPPCF's goal is to provide comprehensive training of industry and governmental technicians and scientists to help the burgeoning industry develop advanced biotherapeutic characterization. The new facility will also educate scientists on existing and upcoming U.S. and European drug regulations.

"The combination of Pauline Rudd's expertise in glycan analysis and Waters technology for analysis of complex biological samples provides a unique combination of capabilities that can help underpin Ireland's continued reputation as a centre of excellence for the very highest quality standards in biopharmaceutical manufacturing," commented Minister Sherlock. "I'm truly delighted to announce this collaboration as it will surely assist both NIBRT and Waters in further cementing their reputation as providers of choice for the biopharmaceutical industry and Ireland's reputation as a world leading location for biotech manufacturing." He added, "It's a privilege for me to acknowledge this collaboration, to congratulate Pauline and to see that the collaboration between NIBRT and Waters continues to flourish."

Waters is the leader in biopharmaceutical analytical technology, which is fundamental to the advancement of biopharmaceuticals. The company offers a comprehensive technology solution that gives biopharmaceutical manufacturers the analytics they need from discovery to development to commercialization and everything in between.

Waters' effort with NIBRT is the latest demonstration of the company's commitment to creating partnerships that enable it to multiply its impact on critical public health issues, including food safety, safe drugs and clean water.

About Waters Centers of Innovation Program

Waters Centers of Innovation Program recognizes and supports the efforts of scientists facilitating breakthroughs in health and life science research, food safety, environmental protection, sports medicine and many other areas.

Prof. Rudd joins 19 others researchers and research centers recognized by Waters' Centers of Innovation Program. The others include Professor Jeremy Nicholson, Imperial College London; Professor John Engen, Northeastern University, Boston, Mass.; Professor James Scrivens, University of Warwick, Coventry, UK; Professor David Cowan of Kings College London; Professor Arthur Moseley of Duke University, Durham, North Carolina; Professor Julie Leary of the University of California - Davis; and Professor Albert J. Fornace, Jr., Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.; Professor Marcos Eberlin, University of Campinas, Brazil; Dr. Chang Hsu, Future Fuels Institute, Tallahassee, Florida; Professor Ganesh Anand, National University of Singapore; Dr. Konstantinos Petritis, Translational Genomics Research Institute, Phoenix, Arizona; Professor Vladimir Shulaev, University of North Texas Department of Biological Sciences, Denton, Texas; Dr. Joseph Dalluge, University of Minnesota: Prof. Sarah Trimpin, Wayne State University; Dr. Frank Gonzalez, National Cancer Institute; Dr. Devin Peterson, University of Minnesota, Caroline West and Eric Lesselier, Universite d'Orleans; and Professor Burt van Bavel, Orebro University.

These leading scientists, in partnership with Waters, are using liquid chromatography and mass spectrometry to take research down new paths and help unlock the mysteries of science.


The National Institute for Bioprocessing Research and Training, Dublin, Ireland is a centre of excellence that supports the biopharma sector by offering research platform solutions for bio-manufacturing and provides tailored accredited industrial training and academic educational programmes to students in purpose-built flexible and modern bioprocessing facilities that will facilitate the expansion of the biopharma sector in Ireland. For further information, please refer to www.nibrt.ie.

For over 50 years, Waters Corporation (NYSE:WAT) has created business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.85 billion in 2011, Waters is driving scientific discovery and operational excellence for customers worldwide.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
05/18INSIDER TRADING ACTIVITY WATERS CO. : WAT) – VP Sold 3,521 shares of Stoc..
05/15WATERS CORP /DE/ : Amendment or Waiver to Code of Ethics, Financial Statements a..
05/11WATERS CORPORATION (NYSE : WAT) Files An 8-K Submission of Matters to a Vote of ..
05/11WATERS CORP /DE/ : Submission of Matters to a Vote of Security Holders (form 8-K..
05/04WATERS CORP /DE/ : Management's Discussion and Analysis of Financial Condition a..
05/03WATERS : New Mass Spectrometry Study Findings Recently Were Reported by Research..
05/03WATERS CORPORATION NYSE : WAT Reports First Quarter 2018 Financial Results
05/01WATERS CORPORATION : Presentation at the Deutsche Bank 43rd Annual Health Care C..
04/26WATERS : Findings on Analytical Chemistry Reported by Investigators at Waters Co..
More news
News from SeekingAlpha
05/26Tracking Al Gore's Generation Investment Management Portfolio - Q1 2018 Updat.. 
05/10Waters (WAT) Presents At 43rd Annual Deutsche Bank Healthcare Conference - Sl.. 
05/08METTLER TOLEDO : Still Not Attractive Enough 
04/26Earnings Season's Biggest Winners And Losers... So Far 
04/24Waters' (WAT) CEO Chris O'Connell on Q1 2018 Results - Earnings Call Transcri.. 
Financials ($)
Sales 2018 2 468 M
EBIT 2018 760 M
Net income 2018 628 M
Finance 2018 1 316 M
Yield 2018 -
P/E ratio 2018 24,18
P/E ratio 2019 21,82
EV / Sales 2018 5,52x
EV / Sales 2019 5,34x
Capitalization 14 936 M
Duration : Period :
Waters Corporation Technical Analysis Chart | WAT | US9418481035 | 4-Traders
Technical analysis trends WATERS CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 207 $
Spread / Average Target 8,7%
EPS Revisions
Christopher James O'Connell Chairman, President & Chief Executive Officer
David A. Terricciano Senior Vice President-Global Operations
Sherry L. Buck Chief Financial & Accounting Officer, SVP
Edward W. Conard Independent Director
Michael J. Berendt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ROYAL PHILIPS15.19%39 823